Dose-related morphological changes in the epididymal region of sexually active adult male Japanese quail treated with di-n-butyl phthalate (DBP) commencing during the pre-pubertal stage

Di-n-butyl phthalate (DBP) is widely used as a plasticizer in personal care and medical products and is known to induce toxicity in the male reproductive organs in both mammals and birds. In this study, there was investigation of the effects of DBP on the epithelium of the rete testis, proximal, and distal efferent ductules and epididymal duct of adult Japanese quail (Coturnix japonica) following treatment with varying doses during the pre-pubertal and peri-pubertal periods. Pre-pubertal quail (n = 25) 4 weeks post-hatching were dosed orally with 10, 50, 200 and 400 mg DBP/kg/d, for 30 days and control birds were administered corn-oil only (n = 5 per group). Histo-metrically, there was lesser (P <  0.001) epithelial heights of the rete testis and efferent ductules in all quail DBP-treated groups, but not in the epididymal duct epithelium. There were no morphological change effects as a result of DBP treatments in the rete testis epithelium, while there were epithelial cytoplasmic vacuoles detected in the distal efferent ductule and epididymal duct of birds treated with 50, 200 and 400 mg DPB/kg/d. There were several lesions, including degenerative changes, cytoplasmic vacuoles, apoptosis and autophagy in the epithelium of the proximal efferent ductule in quail treated with 200 and 400 mg DBP/kg/d. Overall, the results indicate that treatment with DBP during the pre-pubertal period induced dose-dependent histometric and morphological changes in the epithelium of the epididymal region. It is concluded that the proximal efferent ductule was a highly sensitive component of the epididymal tissues of Japanese quail following treatment with DBP during the pre-pubertal period.The National Research Foundation of South Africahttps://www.elsevier.com/locate/anireproscihj2022Paraclinical Science

Effect of di(n- butyl) phthalate on the blood–testis barrier during puberty onset

DATA AVAILABILITY : The data that support the findings of this study are available from the corresponding author upon reasonable request.Di(n-butyl) phthalate (DBP) is considered a substance of serious concern because of its reproductive toxicity and endocrine-disrupting properties. Exposure to DBP causes morphological and functional changes in the male reproductive system of birds and mammals. However, there are no detailed reports on the effects of DBP on the Sertoli cell and junctional complexes of the blood–testis barrier (BTB) in birds. The present study investigated dose-related ultrastructural changes in Sertoli cells and junctional complexes of the BTB in adult Japanese quail (Coturnix coturnix japonica) exposed to DBP prior to puberty. A total of 25 Japanese quail were used for the study. Exposure to DBP doses of 50, 200 and 400 mg DBP/kg/d caused dose-related ultrastructural changes in junctional complexes including dilation and separation, while disruption of cytoplasmic membranes and mitochondria was observed in Sertoli cells. There was a significant difference in the sum of vacuoles, vacuole diameter, nuclear width, nuclear length, nuclear area, sum of damaged spherical mitochondria, width of elongated mitochondria and the sum of damaged elongated mitochondria among the five treatment groups (p ˂ 0.05). Prepubertal exposure to DBP at doses of 50, 200 and 400 mg DBP/kg/d for 30 days led to adverse effects in the adult male Japanese quail reproductive system by inducing structural changes in the Sertoli cells and junctional complexes. Such changes might disrupt the BTB and potentially interfere with spermatogenesis. Results indicated that the Sertoli cell is sensitive to DBP exposure and might be an important cellular target for DBP-induced testicular toxicity.The National Research Foundation.http://wileyonlinelibrary.com/journal/ahe2024-01-06Anatomy and PhysiologyParaclinical SciencesProduction Animal Studie

Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

Background The European Atherosclerosis Society Familial Hypercholesterolaemia Studies Collaboration (FHSC) global registry provides a platform for the global surveillance of familial hypercholesterolaemia through harmonisation and pooling of multinational data. In this study, we aimed to characterise the adult population with heterozygous familial hypercholesterolaemia and described how it is detected and managed globally. Methods Using FHSC global registry data, we did a cross-sectional assessment of adults (aged 18 years or older) with a clinical or genetic diagnosis of probable or definite heterozygous familial hypercholesterolaemia at the time they were entered into the registries. Data were assessed overall and by WHO regions, sex, and index versus non-index cases. Findings Of the 61 612 individuals in the registry, 42 167 adults (21 999 [53·6%] women) from 56 countries were included in the study. Of these, 31 798 (75·4%) were diagnosed with the Dutch Lipid Clinic Network criteria, and 35 490 (84·2%) were from the WHO region of Europe. Median age of participants at entry in the registry was 46·2 years (IQR 34·3–58·0); median age at diagnosis of familial hypercholesterolaemia was 44·4 years (32·5–56·5), with 40·2% of participants younger than 40 years when diagnosed. Prevalence of cardiovascular risk factors increased progressively with age and varied by WHO region. Prevalence of coronary disease was 17·4% (2·1% for stroke and 5·2% for peripheral artery disease), increasing with concentrations of untreated LDL cholesterol, and was about two times lower in women than in men. Among patients receiving lipid-lowering medications, 16 803 (81·1%) were receiving statins and 3691 (21·2%) were on combination therapy, with greater use of more potent lipid-lowering medication in men than in women. Median LDL cholesterol was 5·43 mmol/L (IQR 4·32–6·72) among patients not taking lipid-lowering medications and 4·23 mmol/L (3·20–5·66) among those taking them. Among patients taking lipid-lowering medications, 2·7% had LDL cholesterol lower than 1·8 mmol/L; the use of combination therapy, particularly with three drugs and with proprotein convertase subtilisin–kexin type 9 inhibitors, was associated with a higher proportion and greater odds of having LDL cholesterol lower than 1·8 mmol/L. Compared with index cases, patients who were non-index cases were younger, with lower LDL cholesterol and lower prevalence of cardiovascular risk factors and cardiovascular diseases (all p<0·001). Interpretation Familial hypercholesterolaemia is diagnosed late. Guideline-recommended LDL cholesterol concentrations are infrequently achieved with single-drug therapy. Cardiovascular risk factors and presence of coronary disease were lower among non-index cases, who were diagnosed earlier. Earlier detection and greater use of combination therapies are required to reduce the global burden of familial hypercholesterolaemia. Funding Pfizer, Amgen, Merck Sharp & Dohme, Sanofi–Aventis, Daiichi Sankyo, and Regeneron